Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice

J Nutr Biochem. 2012 Jul;23(7):768-76. doi: 10.1016/j.jnutbio.2011.04.001. Epub 2011 Sep 1.


Tiliroside contained in several dietary plants, such as rose hips, strawberry and raspberry, is a glycosidic flavonoid and possesses anti-inflammatory, antioxidant, anticarcinogenic and hepatoprotective activities. Recently, it has been reported that the administration of tiliroside significantly inhibited body weight gain and visceral fat accumulation in normal mice. In this study, we evaluated the effects of tiliroside on obesity-induced metabolic disorders in obese-diabetic KK-A(y) mice. In KK-A(y) mice, the administration of tiliroside (100 mg/kg body weight/day) for 21 days failed to suppress body weight gain and visceral fat accumulation. Although tiliroside did not affect oxygen consumption, respiratory exchange ratio was significantly decreased in mice treated with tiliroside. In the analysis of metabolic characteristics, it was shown that plasma insulin, free fatty acid and triglyceride levels were decreased, and plasma adiponectin levels were increased in mice administered tiliroside. The messenger RNA expression levels of hepatic adiponectin receptor (AdipoR)-1 and AdipoR2 and skeletal muscular AdipoR1 were up-regulated by tiliroside treatment. Furthermore, it was indicated that tiliroside treatment activated AMP-activated protein kinase in both the liver and skeletal muscle and peroxisome proliferator-activated receptor α in the liver. Finally, tiliroside inhibited obesity-induced hepatic and muscular triglyceride accumulation. These findings suggest that tiliroside enhances fatty acid oxidation via the enhancement adiponectin signaling associated with the activation of both AMP-activated protein kinase and peroxisome proliferator-activated receptor α and ameliorates obesity-induced metabolic disorders, such as hyperinsulinemia and hyperlipidemia, although it does not suppress body weight gain and visceral fat accumulation in obese-diabetic model mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / genetics
  • AMP-Activated Protein Kinases / metabolism
  • Adiponectin / blood*
  • Adiponectin / genetics
  • Animals
  • Fatty Acids / blood
  • Female
  • Flavonoids / pharmacology*
  • Insulin / blood
  • Intra-Abdominal Fat / metabolism
  • Lipid Metabolism / drug effects*
  • Liver / drug effects*
  • Liver / metabolism
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / etiology
  • Metabolic Diseases / physiopathology
  • Mice
  • Mice, Obese
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / metabolism
  • Obesity / complications
  • Obesity / drug therapy
  • Obesity / physiopathology
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • Plant Extracts / pharmacology*
  • Receptors, Adiponectin / genetics
  • Receptors, Adiponectin / metabolism
  • Signal Transduction
  • Triglycerides / blood
  • Up-Regulation
  • Weight Gain / drug effects


  • Adiponectin
  • Fatty Acids
  • Flavonoids
  • Insulin
  • PPAR alpha
  • Plant Extracts
  • Receptors, Adiponectin
  • Triglycerides
  • adiponectin receptor 1, mouse
  • adiponectin receptor 2, mouse
  • tiliroside
  • AMP-Activated Protein Kinases